Insights
Integrated Solutions
Rooted in the Patient Experience
Across the Product Life Cycle
Related Articles
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB […]
The Need for RWE Studies in APAC and the Impact on Product Life Cycle Management
Advances in technology and globalization have enabled significant growth in the pharmaceutical industry over the last decade. Digital initiatives and focusing on patients have also conditioned researchers to think beyond traditional data collection to support product value propositions. As a result, real-world evidence (RWE) is gaining in importance and becoming an important part of managing […]
Health Technology Assessment in the Asia Pacific Region
Health technology assessment (HTA) is the systematic evaluation of the properties and effects of a health technology, addressing the direct and intended effects of the technology as well as its indirect and unintended consequences. In many countries, it is a primary evaluation tool for making pricing and access decisions, providing a platform for understanding economic […]
Building a Life Sciences Digital Ecosystem
In the life sciences world, we hear more and more of the requirement for digital ecosystems in various therapies. What do we mean by these, and what benefits do they provide? A digital ecosystem is a network of multiple stakeholders who collaborate to enhance delivery to patients. A healthy, sustainable ecosystem benefits patients, prepares companies […]
Assessing Market Opportunity and Entry Challenges in Mental Health Disorders
Although mental health disorders affect almost 264 million people worldwide, they are often misunderstood and misdiagnosed, and access is poor. The World Health Organization (WHO) reports that 80% of people in low- and middle-income countries receive no treatment for their mental health disorders. As well as being underdiagnosed, mental health disorders are also poorly studied […]
Increasing the Value of Community Health Workers
In developing countries, frontline community health workers (CHWs) extend basic healthcare services to communities. These extensive CHW networks provide services that improve various health indicators. The Philippines has set a goal of one CHW (“Barangay Health Worker”) in every village, while India is close to meeting its goal of one CHW (“ASHA”) per 1,000 people […]
Novel Antibiotic Opportunity in China
China, with its large population and extensive healthcare system, is the second-highest user of antibiotics in the world. Such widespread use has inevitably led to high levels of antibiotic resistance in the population. When isolated, it becomes clear that a significant majority of the infecting bacteria are gram-negative. Within these bacteria, antibiotic resistance has grown […]
Digital Therapeutics: Where Technology Meets Healthcare
Digital health is growing rapidly across the world, supported by technologies that not only assist disease monitoring or prevention but can also reduce the healthcare burden. Digital technologies have improved equity of access and enabled European patients to monitor and self-manage their health. It has improved efficiency, effectiveness and quality of patient care while also […]
Adapting Patient Access Programs to Asia
In Western markets, pharmaceutical companies have developed many approaches to patient access programs (PAPs), normally emphasizing initiatives that, while helping patients, also support pricing and reimbursement initiatives, such as: Early access programs before market authorization. Financial access initiatives before achieving reimbursement. Value-based contracts, managed-entry agreements or outcomes-based programs for achieving reimbursement. Non-financial assistance post-reimbursement. The […]
The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?
Time and strategy are keys to launching in an overwhelmed, unpredictable market. Pharmaceutical companies in mid-development of a drug need to look ahead at their launch strategy options and consider what market conditions could look like by the time they’re ready to commercialize their product. By evaluating the value of an asset early in development, pharma companies can gain a better understanding of a product’s value and risk. With assessment insights, manufacturers can make informed clinical and commercial […]
Case Study: Early-Stage Asset Valuation
The rewards of developing a new drug can be very attractive but they come with inherent risks. It is important to ensure that investment decisions on clinical development are made after examining the risk profile of the drug which depends on the therapy area and the nature as well as extent of unmet needs. EVERSANA […]
The Importance of Digital Strategy in Pharma in the APAC Region
The Asia Pacific region continues to show great progress in digital health as pharmaceutical companies look at digital technologies as a tool to drive access and to start developing their digital strategies. To understand the strides and recent evolution of digital in pharma, our APAC team conducted a survey with top pharmaceutical companies in the […]
Improving Patient Outcomes Through Digital Health
Digital applications can work cohesively with therapeutics in the treatment of a broad range of diseases, from behavioral health to chronic conditions. In an interview with Debraj Dasgupta, Head of Strategy & Go-to-Market Planning at Nippon Boehringer Ingelheim Co., Ltd., Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, […]
The Digitalization of Healthcare in Asia Pacific
The digitalization of healthcare in Asia Pacific is being utilized to enhance the patient-centered approach and expanding access to health. In a candid conversation with Abhishek Shah, CEO at Wellthy Therapeutics, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, uncovered the current healthcare landscape and how digital strategy […]
The Regulatory Landscape in Digital Health
Despite the advances in digital health and digital therapeutics in recent years, there remains an ambiguity in the digital space and uncertainty surrounding regulation and reimbursement of digital technologies applied to pharma, biopharma and medical device companies. In an insightful conversation that was part of EVERSANA’s Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances […]
Access to Technology and the Rise of Digital Health in Asia Pacific
The access to technology, development of telehealth and evolution of digital therapeutics are thriving in Asia Pacific; and pharmaceutical companies are levering the momentum to reach to a broader segment of the patient population. Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, interviewed Anish Shindore, Head of Digital […]
Digital Innovation in Asia Pacific
Digital medicine and digital therapeutics are transforming the healthcare industry by changing the care delivery format, and they have the potential to improve patient adherence and outcomes. In our recent Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, interviewed David Keene, CEO at IntroSpect Digital Therapeutics […]
Outlook: Digital & Pharma in Asia Pacific
Asia Pacific is one of the fastest-growing regions for digital innovation in the pharmaceutical and biotechnology industries. Its promising outlook is mainly driven by necessity, commercial flexibility and a broad talent pool. In a candid conversation broadcasted during the EVERSANA’s Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine, […]
Leading and Decision-Making in Uncertain Times
By definition, leaders must have followers, who are defined as people who must be shown the way. While this is within most leaders’ grasps when the road ahead is straight and wide and the destination is visible, more is demanded of them when the road splits, narrows and dusk falls. The current crisis presents special […]
Oncology Treatment Access in 2020 and Beyond
2020 promises to be eye-opening as the coming election will surely provide clarity to the path that we will be taking for oncology treatment access. From international reference pricing, acceleration of biosimilars and generics, and allowance of reimportation – pressure continues to mount to reduce pharmaceutical prices, especially those used to treat cancer. Much of […]
Realizing Value from Digital in the Healthcare Environment [Webinar]
[WEBINAR – 20 MINUTES] The advancements of Digital Therapies are promising but commercial success is not always guaranteed. This presentation explores the pitfalls and challenges of selling products into the uniquely complicated and regulated healthcare market. It will lay the groundwork for digital companies to have successful commercial strategies and be able to: Answer questions […]
The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need
The “Great Gatsby Era” was an exciting time of new prosperity, infinite creativity and dramatic social change. Long-standing social norms and traditions gave way to the “mass culture” and consumerism that modernized American society. “What will they think of next?” was a popular expression that defined the era. On the 100-year anniversary of this revolutionary […]
Improving the Impact of an Oncology Patient Access Program
Our client, a specialty pharmaceutical company focused on the research and development of new therapies in two high-cost complex drug categories, sought to benchmark its patient assistance program against those of its competitors in order to improve relationships within target oncologists’ offices. The Challenge The client needed to assess the image of its patient assistance […]
Strategies to Ensure Market Success of a Rare Disease Product Launch
Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider in your launch strategy: Market dynamics impacting rare disease therapies The entire rare community: patients, caregivers, providers & advocates […]
After FDA Approval, Can Gene Therapies Achieve Marketing Success?
Without a doubt, gene therapy is transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. There are more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease. With a market that is fragmented, there is a need for an innovative, end-to-end […]
Global Biosimilar Competitor Assessment – Who Wins in Biosimilar Access and Why?
The introduction of biosimilar products has created interesting changes in payer behavior across the global markets. For both innovator and biosimilar companies, it has been an effort to understand the demands of payers and succeed in what looked like a ‘winner-takes-all’ opportunity. As the first round of biosimilar introductions has passed, there are some interesting […]
Innovative Therapies Call for an Integrated Drug Safety and Compliance Model
In this article, Herbert Lee, PharmD, Senior Vice President, Medical Communications and Pharmacovigilance, makes the case for an integrated approach to ensuring the safe and effective use of medications by patients. From emerging therapies to innovative technologies, the healthcare industry is changing – demanding that we do business differently. Working in one of the most […]
Gene Therapy for Rare Disorders
With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?
‘Tis the season for pharma in China, as the government expedites uptake of new urgently needed drugs
PRICENTRIC BRIEF: Universal health insurance coverage for 1.3 billion people means China must increase uptake of “clinically urgently needed new drugs” already approved in the US, EU, and Japan Mostly oncology products are being imported, along with HIV/AIDS medicines Pharma is agreeing to steep discounts to be reimbursed on China’s national drug lists THE DETAILS […]